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Abstract
Angiogenesis is the process by which new blood vessels arise from existing ones by the budding out of endothelial cell
capillaries from the luminal side of blood vessels. Blood vessel formation is essential for organ development during
embryogenesis and is associated with several physiological and pathological processes, such as wound healing and tumor
development. The VE-statin/egfl7 gene is specifically expressed in endothelial cells during embryonic development and in
the adult. We studied here the regulatory mechanisms that control this tissue-specific expression. RT-qPCR analyses showed
that the specificity of expression of VE-statin/egfl7 in endothelial cells is not shared with its closest neighbor genes notch1
and agpat2 on the mouse chromosome 2. Chromatin-immunoprecipitation analysis of histone modifications at the VE-
statin/egfl7 locus showed that the chromatin is specifically opened in endothelial cells, but not in fibroblasts at the
transcription start sites. A 13 kb genomic fragment of promoter was cloned and analyzed by gene reporter assays which
showed that two conserved regions are important for the specific expression of VE-statin/egfl7 in endothelial cells; a28409/
27563 enhancer and the 2252/+38 region encompassing the exon-1b transcription start site. The latter contains essential
GATA and ETS-binding sites, as assessed by linker-scanning analysis and site-directed mutagenesis. An analysis of expression
of the ETS and GATA transcription factors showed that Erg, Fli-1 and GATA-2 are the most highly expressed factors in
endothelial cells. Erg and GATA-2 directly control the expression of the endogenous VE-statin/egfl7 while Fli-1 probably
exerts an indirect control, as assessed by RNA interference and chromatin immunoprecipitation. This first detailed analysis of
the mechanisms that govern the expression of the VE-statin/egfl7 gene in endothelial cells pinpoints the specific importance
of ETS and GATA factors in the specific regulation of genes in this cell lineage.
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Introduction
The endothelium is a monolayer of cells which lines the blood
vessel luminal side, in direct contact with the circulation. It forms,
in most locations, a tight and selective barrier between the organs
and blood. Endothelial cells participate to or regulate thrombosis,
leukocyte extravasation, vasodilatation, and angiogenesis. They
express most specifically several markers which define their
identity. The mechanisms regulating expression of many such
markers have been analyzed, such as the VEGF receptor genes flk-
1 [1,2] and flt-1 [3,4], the junction molecule VE-cadherin [5,6] or
the receptors robo-4 [7,8], tie-1 [9,10], and tie-2 [11,12]. In most
cases, specific gene expression is regulated by a set of discrete
binding sites for ETS and GATA factors. Recent data showed that
a combination of Forkhead and ETS factors binding sites could
also be important for the regulation of endothelial gene promoters
[13,14]. In addition to cis-acting regulation, epigenetic modifica-
tions directly participate to the endothelial-specific regulation of
gene expression; eNOS is highly methylated in non-endothelial cells
and is enriched in acetylated H3 and H4 histones in the regions
surrounding the promoter and the transcription start site in
endothelial cells [15,16]. Notch4 is specifically enriched in
acetylated histones along its regulatory regions in the first intron
and third exon in endothelial cells [17]. Other endothelial genes
such as endothelial protein C receptor epcr [18] and von
Willebrand factor vwf [19] are also epigenetically regulated in
endothelial cells.
We have initially characterized the Vascular Endothelial-statin/
epidermal growth factor-like 7 (VE-statin/egfl7) gene as being specifically
and strongly expressed in endothelial cells in vitro and in vivo [20].
VE-statin/egfl7 is expressed very early during mouse development;
at E7.5, VE-statin/egfl7 expression is detected exclusively in the
primitive blood islands where the first endothelial cells differen-
tiate. Then after during embryogenesis and in the newborn, VE-
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statin/egfl7 is expressed in endothelial cells of arteries, veins and
capillaries [20,21]. Expression of VE-statin/egfl7 decreases in adult
tissues, though maintaining its endothelial-specific distribution
(Soncin F. not shown, [21]). Of note, VE-statin/egfl7 expression was
also detected at transient and low levels in primordial germ cells
[22] and in a subtype of neurons of the mouse adult brain [23] but
overall, VE-statin/egfl7 is an excellent marker of the endothelial
lineage for which the gene regulation has not been studied in
details so far.
VE-statin/egfl7 encodes a 30kDa secreted protein which
represses the migration of smooth-muscle cells in response to
PDGF-BB in vitro [20]. VE-statin/egfl7 is also an endogenous
negative regulator of elastogenesis which prevents the deposition of
elastin by endothelial cells [24]. Unfortunately, the reported gene
inactivation approaches have been more troublesome than
anticipated [25,26] and we are still in need of a detailed
description of the phenotype.
In this study, we describe the first analysis of the regulatory
mechanisms that are responsible for the specific expression of VE-
statin/egfl7 in endothelial cells. We identified several important
regulatory regions and sites and showed that expression of VE-
statin/egfl7 is directly regulated by the Erg and GATA-2
transcription factors and indirectly by Fli-1.
Materials and Methods
Bioinformatics
Comparative genomic analyses and transcription factor binding
site prediction were performed using the 30-Way Multiz
Alignment & Conservation module of the University of California,
Santa Cruz Genome Bioinformatics site (genome.ucsc.edu) and
the Genomatix suite (http://www.genomatix.de), respectively.
Relevant data were analyzed for statistical significance in the
Student’s t-test using Analyse-it for Microsoft Excel (version 2.03,
Analyse-it Software, Ltd.)
Cells
H5V [27], EOMA (ATCC CRL-2586), 1G11 [28] and MS1
(ATCC CRL-2279) mouse endothelial cells, or 3T3 (ATCC CRL-
1658) and L929 (ATCC CCL-1) fibroblasts were cultured in
78.5 cm2 dishes (Falcon) in Dulbecco’s Modified Eagle’s Medium
(Invitrogen), 10% calf or fetal calf serum (Hyclone), 10kU/L
penicillin, 10 mg/L streptomycin. Non-essential amino acids and
Na-pyruvate were added to 1G11 culture medium. Cells were
cultured in a humidified 95% air/5% CO2 incubator at 37uC and
passaged by standard trypsinisation and 1/5 or 1/10 dilution.
Primary human umbilical vein endothelial cells (HUVEC, Lonza)
were grown in EGM-2 (Lonza) in 25 cm2 ventilated flasks in a
humidified 95% air/5% CO2 incubator at 37uC. They were
passaged by trypsinisation, rinsed in trypsin neutralization solution
(TNS, Lonza) and plated at 5000 cell/cm2 density. They were
used between passage 2 and 7.
Cloning and mutagenesis
Cloning techniques were essentially as described [29]. A 13.0kb
genomic fragment corresponding to the 212969/+38 sequence of
the VE-statin/egfl7 promoter was recovered by NheI/SalI digestion
of a mouse genomic clone and inserted into the NheI/XhoI
restriction sites of pGL3basic (Promega). Deletion constructs were
prepared by ligating the fragments AfeI/SalI (28409/+38), AflII/
SalI (27563/+38), DraI/SalI (25133/+38) NdeI/SalI (22823/
+38) and the HpaI/SalI (21768/+38) into the blunted NheI and
the XhoI site of pGL3basic. The 2668/+38 region was obtained
by digestion of the original mouse genomic fragment with XhoI
and SalI and cloned into the XhoI site of pGL3basic in order
to generate 2668/+38Luc. The 2476/+38 region was generated
by PCR amplification of the original mouse genomic fragment
with the primers 59-atatgctagccctggttgcacgcagctccag and 59-aat-
gtctgctgcccagggtc. The 2252/+38 region was generated by PCR
amplification of the original mouse genomic fragment with 59-ata
tgc tag cgt ctc tga ctg ctt cag g and 59-aat gtc tgc tgc cca ggg tc.
The 2124/+38 region was obtained by digestion of the original
mouse genomic fragment with BamHI and SalI. These 2476/
+38, 2252/+38 and 2124/+38 fragments were cloned into the
NheI and XhoI sites of pGL3basic in order to generate the 2476/
+38Luc, 2252/+38Luc and 2124/+38Luc vectors, respectively.
Cloning of28409/27563-SV40Luc and27563/28409-SV40Luc
were performed by digesting the original mouse genomic fragment by
AflII/Eco47III and inserting the 846 bp fragment in either orientation
in the SmaI site of the pGL3promoter vector (Promega). Cloning of the
7770/27563-SV40Luc vector was performed by PCR amplification of
28409/27563-SV40Luc using the 59-atctcgaggtcatggtgcacaaggagga-
ag and 59-atgagctcgtgcctgaccctgaagcctg primers, digestion of the PCR
fragments with SacI and XhoI and cloning into the corresponding sites
of pGL3promoter.
Site-directed mutagenesis was performed using the overlap
extension method [30]. Two separate amplification reactions were
first performed using 2252/+38Luc (30.1 fmoles) as template; one
using the RVprimer3 (Promega, 0.5 mM) and the mutated reverse
primer (0.5 mM, Table S1), the other using the mutated forward
primer and the GLprimer2 (Promega) with either native Pfu
polymerase (Stratagene) or High Fidelity PCR master Mix (Roche)
in the recommended buffer in the presence of 5% DMSO when
needed. An overlapping reaction was performed using products
from the first PCR (2–5%) and the forward and reverse primers. In
both instances, thermal conditions were 95uC/5min, 25 cycles
[94uC/30s, 55uC/30s, 72uC/30s-1min], 72uC/7min. PCR prod-
ucts were inserted into the NheI/HindIII site of pGL3basic. The
28409/+38EBS6mtLuc and 28409/+38EBS7mtLuc were con-
structed by exchanging the non-mutated DrdI/SalI fragment of
28409/+38Luc for the corresponding mutated versions of the
EBS6 or EBS7 site, respectively. The 28409/+38GATAmtLuc,
28409/+38EBS1mtLuc to 28409/+38EBS5mtLuc vectors were
constructed by exchanging a non-mutated BamHI fragment
spanning the 28409/+38 sequence and part of pGL3basic from
28409/+38Luc for the corresponding mutated versions of the
GATA or of EBS1 to EBS5 sites, respectively. The 28409/
+38mtDLuc was constructed by removing the 2252 /254 region
from 28409/+38Luc.
Linker-scanning analysis
Region A. Two separate amplification reactions were per-
formed using 212969/+38Luc (8.6 fmoles) as template; one using
a forward primer (0.25mM) and ScanA_n_rev primers (0.25mM,
Table S1), the other using the ScanA_n_forward primer and a
reverse primer using native Pfu polymerase (Stratagene) in the
supplied buffer containing 0.15mM dNTPs and 5% DMSO.
Thermal conditions were 95uC/5min, 25 cycles [94uC/30s,
55uC/30s, 72uC/2min], 72uC/7 min. An overlapping PCR was
then performed by mixing products from the corresponding first
reactions (2%) and the forward and reverse primers. Thermal
conditions were 95uC/5min, 5 cycles [94uC/30s, 62uC/30s,
72uC/1.5min], 25 cycles [94uC/30s, 62uC/30s, 72uC/1.5min],
72uC/7 min. PCR products were digested and inserted into the
NheI/AflII sites of 212969/+38Luc.
Region D. A similar scheme was applied except that the first
amplification reactions were performed using 2252/+38Luc
(30.1fmoles) as template and the ScanD_n_fwd/GLprimer3 and
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RVprimer2/ScanD_n_rev primers, respectively (Table S1) using
High Fidelity PCR Master Mix (Roche) in the supplied buffer and
5% dimethylsulfoxide. Thermal conditions were 95uC/5min, 33
cycles [94uC/30s, 55uC/30s, 72uC/30s], 72uC/7 min. Overlap-
ping amplifications were performed using the RVprimer3 and
GLprimer2 primers. Thermal conditions were 95uC/5min, 33
cycles [94uC/30s, 55uC/30s, 72uC/50s], 72uC/7 min. PCR
products were digested and inserted into the NheI/HindIII site
of pGL3basic. Vectors were transformed and then produced in
Novablue (Novagen) or TG1 bacteria and purified in endotoxin-
low conditions (PureLinkTM HiPure Plasmid, Invitrogen). Inserts
were fully sequenced on both strands (Genoscreen, Lille).
Transient transfection and transactivation assays
Cells were plated at 15000 cells/cm2 in 10cm2 plates, grown
overnight and transfected with 80 fmoles of the luciferase reporter
vector indicated in the figures, 70 fmoles of transactivation vector
where indicated, and 54 fmoles pCH110 b-galactosidase normal-
ization vector in OptiMEM (Invitrogen) and in the presence of
Exgen 500 reagent (3ml/mg DNA, Euromedex) for 6hr at 37uC in a
5%CO2/95% air atmosphere. Total DNA content was adjusted to
1.5mg/well with pUC19. Transfection medium was changed for
culture medium and the cells cultured for further 48hr after which
they were rinsed with PBS and lysed in Reporter Lysis buffer
(Promega). HUVEC were transfected in similar conditions but
using Superfect (50ml/mg of DNA, Lonza) as a transfecting agent
instead of Exgen-500 and incubating the cells in the presence of
DNA for 3h instead of 6h. Cell extracts were assayed for luciferase
and b-galactosidase activity using the Luciferase assay system
(Promega) and the TROPIX galacto-light b-galactosidase reporter
gene assay (Applied Biosystems), respectively. The luciferase value
of each sample was normalized with its b-galactosidase value.
RNA interference
Cells were seeded at 15000cells/cm2 in 10cm2 dishes, cultured
overnight and transfected with 200 to 400pmoles of small
interfering RNA (siRNA) designed for each target (SilencerH
Select Pre-designed siRNA, Applied Biosystems or ON-TAR-
GETplus SMARTpools, Dharmacon) mixed in 0.5 ml OptiMEM
with Lipofectamine 2000 (10ml, Invitrogen) and cultured 48h
before RNA extraction and qPCR analysis; Alternatively, cells
were lysed in 62.5 mM TRIS-HCl, pH 6.8, 2% SDS, 5% glycerol,
0.28M b-mercaptoEtOH, 0.03% Bromophenol blue, extracts
were boiled 3 min before proceeding with SDS-PAGE and
Western-blotting.
Western-blotting
Cell extracts were analyzed by 12% SDS-PAGE and protein
transferred onto a PVDF membrane (Immobilon-P, Millipore)
overnight at 4uC at 30V under constant stirring of the buffer.
Membranes were incubated in PBS, 0.05% Tween-20, 5% non-fat
dry milk (Soleil d’Agadir, Lille) for 3h at room temperature and
incubated with antibodies directed against VE-statin/egfl7 (1/500,
sc-66874), Erg (1/5000, sc-354x, Santa-Cruz), Fli-1 (1/1000, sc-
356x, Santa-Cruz), Ets-1 (sc-111x, Santa Cruz), GATA-2 (1/2500,
sc-9008x, Santa-Cruz), GATA-4 (1/2500, sc-1237x, Santa-Cruz),
or beta-actin (1/1000, sc-1615) in PBS, 0.05% Tween-20, 5%
non-fat-dry milk overnight at 4uC under constant mixing, rinsed
three times 10 min with PBS, 0.25% Tween-20 at room
temperature and further incubated with an horseradish perox-
ydase-coupled anti-goat, mouse, or rabbit antibody (1/10000,
A9452-1VL Sigma, NA931VS, or NA934VS GE-Healthcare,
respectively) in PBS, 0.05% Tween-20, 5% non-fat dry milk,
rinsed three times in PBS, 0.25% Tween-20 and immunocom-
plexes were revealed using the Western Lightning-ECL kit (Perkin-
Elmer) after exposure to Hyperfilm ECL (GE-Healthcare).
RNA extraction and reverse transcription
Total RNA were extracted from cells using either Trizol reagent
(Invitrogen) or RNeasy kit (Qiagen) and treated with DNaseI
reagent (Macherey-Nagel) for 30 min at room temperature.
Reverse transcriptions were performed using 1mg total RNA and
the High capacity cDNA reverse transcription kit with RNase
Inhibitor (Applied Biosystems).
Chromatin immuno-precipitation
Chromatin immunoprecipitation was performed using Magna-
ChIP (Millipore) according to the manufacturer’s instructions and
the following antibodies: Erg; sc-354x (Santa-Cruz), Fli-1; sc-356x
(Santa-Cruz), Ets-1; sc-111x (Santa Cruz), GATA-2 sc-9008x
(Santa-Cruz), GATA-4; sc-1237x (Santa-Cruz), acetyl-histone H3;
06-599 (Millipore), dimethyl-histone H3 (Lys4); 07-030 (Millipore),
acetyl-histone H4; 06-866 (Millipore), irrelevant antibody; anti-
HA.11, MMS-101R (Convance). Briefly, H5V endothelial cells
were plated at 15000 cells/cm2 and cultured for two days and
incubated in culture medium containing 1% formaldehyde for
10 min at 37uC. The reaction was then quenched with 0.125M
glycine, the cells were lysed in Lysis buffer containing Protease
Inhibitor Cocktail II and disrupted at 4uC using a sonicator
(Bioruptor, Diagenode, 20 pulses of 1 min with 1 min intervals) in
order to shear the genomic DNA in 1000 bp average-size
fragments (not shown). The cell extracts were cleared by
centrifugation at 10000g at 4uC for 10 minutes and aliquoted in
50 ml (1.106 cells). For each condition, a 50 ml aliquot was mixed
with 450 ml Dilution buffer containing protease inhibitor cocktail
II. A 5 ml sample corresponding to INPUT was collected at this
point. Extracts were mixed with 5 mg of either antibody and with
20 ml of Magnetic Protein A beads slurry and incubated overnight
at 4uC on a rotating wheel. Beads were then washed successively
with 0.5 ml Low Salt Immune Complex Wash buffer, High Salt
Immune Complex Wash Buffer, LiCl Immune Complex Wash
Buffer, and TE Buffer at 4uC. Immunocomplexes were eluted in
100 ml ChIP Elution Buffer containing Proteinase K and
incubated for 2 hr at 62uC prior to inactivation at 95uC for
10 min. DNA purification was performed using the provided spin
filters, recovered in a 50 ml final volume of Elution Buffer C and
stored at 220uC until PCR analysis.
Quantitative PCR (qPCR)
qPCR following chromatin immunoprecipitation.
qPCR were performed in PCR SYBR Green I mix (Roche)
containing 10 pmoles of each indicated primer (Table S2). PCR
consisted in 40 cycles of [95uC/10s, annealing temperature/10s,
72uC/25s] using the primers and conditions listed in Table S2.
Data are expressed as 22DCt where DCt=Ct of sample – Ct of
INPUT.
qPCR for VE-statin/egfl7 expression. VE-statin/egfl7 and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) transcripts
were quantified in duplex FRET PCR reactions using a
LightCycler 2.0 (Roche) and the following oligonucleotides:
mVE-statin/egfl7 primers 59-agcatggtttctagtgttg and 59-ctacggcga-
taggcagt and fluorescent probes 59-ggagacctttgtgcagcgt-Fluo and
Red640-ataccagccttacctcaccac-39, GAPDH primers 59-cttccgtgtt-
cctaccc and 59-gggtttcttactccttgg and the fluorescent probes 59-
tcctgcgacttcaacagcaac-Fluo and Red705-gccactcttccaccttcgatg-39.
PCR reactions were 95uC/10min, 40 cycles [95uC/10s, 55uC/
10s, 72uC/25s]. Alternatively, VE-statin/egfl7 and GAPDH
transcripts were quantified in duplex reactions performed in
VE-statin/egfl7 Expression
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TaqMan Gene Expression Master Mix and the following primers
and probe mixes: VE-statin/egfl7; Mm00618004_m1 EGF-like-
domain 7 Mus musculus TaqMan assay, beta-actin; Mouse ACTB
(actin, beta), GAPDH; mouse GAPDH Endogenous Control
(Applied Biosystems); PCR reactions were 50uC/2min, 95uC/
10min, 40 cycles [95uC/15s, 60uC/1 min]. Levels were calculated
and compared using the DDCt method.
qPCR of GATA and ETS factors, notch1 and agpat-2.
Oligonucleotides were designed using the Primer Express II
software (Applied Biosystems) in order to amplify regions of the
cDNA based on exon-exon junctions and so as to cover at least
two exons (Table S3). qPCR of cDNA were carried out using
Power SYBR Green PCR Master Mix with the following cycles:
95uC/10 min, 40 cycles [95uC/15s, 60uC/1 min] using a
StepOne machine (Applied Biosystems). A melting curve was
determined after each reaction. For each gene, conditions were
setup in order to ensure linearity of amplification over the ranges
analyzed.
Results
Analysis of the chromosome 2 region encompassing the
VE-statin/egfl7 locus
The VE-statin/egfl7 gene is located on the mouse chromosome 2
(Figure 1A) and is composed of 11 exons. Exon-1a and -1b are
initiated from two different transcription start sites (Figure 1B), the
transcript -1b being the most abundant in endothelial cells [20]. In
order to assess whether the VE-statin/egfl7 gene could be located in
a larger cluster of endothelial-specific genes on chromosome 2, the
expression levels of VE-statin/egfl7 and that of its flanking
neighbors notch1 and agpat2 were measured. As already observed
[20], VE-statin/egfl7 expression levels are several tens- to hundreds-
fold higher in endothelial cells than in fibroblasts (Figure 1C).
Notch1 is located 116 kbp ahead of the 59 end of VE-statin/egfl7 and
is expressed in several tissues during mouse development,
including, but not specifically, in endothelial cells, it plays an
important role in angiogenesis [31,32]. Notch1 is not up-regulated
in endothelial cells as it is expressed at similar levels in these cells
and in fibroblasts (Figure 1C). Agpat2 is located 2 kbp after the 39
end of VE-statin/egfl7, it is mostly expressed in adipocytes [33,34].
Agpat2 is expressed at an average 10-times lower levels in
endothelial cells when compared to L929 fibroblasts, its expression
levels are almost non-detectable in 3T3 cells (Figure 1C). VE-
statin/egfl7 is thus not located in a cluster of genes highly expressed
in endothelial cells, suggesting that it holds its own regulatory
signals.
Analysis of the global chromatin structure in the 59 region of
the VE-statin/egfl7 gene showed that the levels of acetylated-
histone H3 (Figure 2A), acetyl-histone H4 and dimethyl-histone
H3 (Lys 4) (Figure S1) were low in all cells in the regions
comprised between 28.0kb and 23.0kb ahead of the transcrip-
tion start site -1b. The levels then increased in endothelial cells
starting at 21kb of the exon-1b and thereafter, while they
remained low in fibroblasts. Altogether combined, these
analyses of histone modifications show that the chromatin is
opened at the VE-statin/egfl7 locus in endothelial cells and
condensed in non-endothelial cells. Accordingly, a treatment of
with the histone deacetylase inhibitor Na butyrate induced a
Figure 1. Structure of the VE-statin/egfl7 gene and promoter. A. Top: schematic representation of the distal region of the mouse chromosome
2. The region encompassing the VE-statin/egfl7 gene is indicated with an arrow. Bottom: distribution of the genes along this region of the
chromosome represented to scale, arrowheads indicate the orientation of the genes. B. Scaled schematic representation of the VE-statin/egfl7 gene.
Arrows indicate the previously identified transcription start sites [20], exons are represented as numbered black boxes. C. Expression levels of notch1,
VE-statin/egfl7, and agpat2 were measured in cultured L929 and 3T3 fibroblasts (white bars), and in 1G11, H5V, EOMA, and MS1 endothelial cells
(black bars) after total RNA isolation and RT-qPCR. Levels of each transcripts were normalized to that of GAPDH measured in the same sample and
represented as fold over mean levels in L929 cells set to 1. Y-axis scales are Log10 representations. *** p,0.001, ** p,0.01, * p,0.05.
doi:10.1371/journal.pone.0012156.g001
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strong rise of VE-statin/egfl7 expression levels in non-endothelial
cells (Figure S2).
Deletion-analysis study of the 59 region of the gene
Highly conserved promoter regions are more likely to contain
important sequences for gene regulation [35]. An alignment and
conservation analysis of human and mouse sequences focusing on the
VE-statin/egfl7 gene regions located ahead of the transcription starts -
1a and -1b showed the presence of several well-conserved regions,
noted A to E (Figure S3). These predicted conserved regions are
located at 27755/27644 (region A), 25414/25174 (B), and
22829/22659 (C, which encompasses exon-1a), 2253/+68 (D)
and +3009/+3068 (E) from the exon-1b transcription start site.
A 13kb genomic fragment corresponding to the sequence located
ahead of exon-1b was isolated and used to construct a series of
luciferase reporter vectors following a 59-deletion strategy based on
the location of the predicted conserved regions. These vectors were
then assessed for basal activity in endothelial cells and in fibroblasts
by transient transfection of H5V and L929 cells, respectively. The
strongest activity levels in both cell types were obtained when the
conserved regions A to D were present in the reporters, such as in
212969/+38Luc and 28409/+38Luc, but with a much higher
activity in endothelial cells than in fibroblasts, leading to a high
endothelial/fibroblast ratio of activity (Figure 3A). In endothelial
cells, 28409/+38Luc was the most active construct, displaying
almost as much activity as the longest 212969/+38Luc but with a
higher endothelial/fibroblast ratio (22.1). Removing the 28409/
27563 fragment, which includes region A, induced a 38% loss of
response in endothelial cells (27563/+38Luc) and a drop of the
endothelial/fibroblast ratio by half (10.6) when compared to
28409/+38Luc. Further deletion of 2.4 kb including region B
(25133/+38Luc) induced another marked drop of activity in both
endothelial cells and fibroblasts, which lost 92% and 75% of that
obtained with 28409/+38Luc, respectively. However, the endothe-
lial/fibroblast ratio remained high (7.1), suggesting that all the
important features for expression of the gene in endothelial cells had
not been lost. Further removal of 2.3 kb (22823/+71Luc) induced
another decrease of the remaining activity by half with no major
incidence on the remaining endothelial/fibroblast ratio. The shortest
construct (21768/+38Luc) displayed a low but yet detectable
activity in endothelial cells, corresponding to a 93% loss of that in
28409/+38Luc but still with an endothelial/fibroblast ratio of 3.4.
Similar results were obtained when these promoter constructs
were tested in human primary HUVEC endothelial cells (Figure
S4), suggesting that the regulatory signals are conserved between
human and mouse endothelial cells.
The 28409/27563 region encompassing region A is an
autonomous enhancer of transcription
Further analysis of the 28409/27563 sequence showed that it
acts as an enhancer of transcription in endothelial cells, as it is able
to activate a minimal promoter reporter regardless of orientation
(Figure 3B). Region A (27770/27563) is the most active region in
this fragment. Despite a linker-scanning analysis of the whole area
(Figure S5) and numerous site-directed mutations (not shown), no
more precise parts of this region were found to be necessary for a
strong activity of the promoter in endothelial cells.
Analysis of the proximal promoter - importance of region
D (2252/+38)
The subsequent analysis was thus focused on the more proximal
21768/+38 sequence of the gene. A progressive 59 deletion
Figure 2. Acetylated Histone H3 levels along the VE-statin/egfl7 promoter. Top. Levels of acetylated-histone H3 along the VE-statin/egfl7
gene were quantified using chromatin immunoprecipitation of 1% formaldehyde-treated cultures of H5V endothelial (N, black bars), L929 (%, white
bars), and 3T3 (D, grey bars) fibroblast DNA followed by sonication, immunoprecipitation of the DNA-protein complexes using an acetyl Histone-H3
antibody (06-599, Millipore), DNA purification and semi-quantitative PCR analysis performed in order to amplify various locations along the promoter
represented along the x-axis. Quantities are relative to the diluted INPUT mean value set to 1. Acetylation levels were low in all cells in the regions
located ahead of the transcription start -1b, they were elevated only in endothelial cells thereafter. Inset: Acetylated-histone H3 levels of the negative
control b-globin and the positive control VE-cadherin gene promoters taken as non- and highly-expressed genes in endothelial cells, respectively, and
assessed in similar conditions. Bottom. Scale schematic representation of the mouse VE-statin/egfl7 promoter and gene, scaled according to the x-
axis in A. Arrows indicate the previously identified transcription start sites [20], exons are represented as numbered black boxes.
doi:10.1371/journal.pone.0012156.g002
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approach was performed based on the proximal 21768/+38
sequence of the gene which comprises the conserved region D.
Removal of 1.1 kb (2668/+38Luc) induced a strong increase of
activity both in endothelial and non-endothelial cells but did not
affect the endothelial/fibroblast ratio when compared to 21768/
+38Luc (Figure 4A), suggesting the presence of a strong inhibitory
sequence in the 21768/2668 region. Further removal of 0.19 kb
(2476/+38Luc) and of an additional 0.22 kb (2252/+38Luc) did
not markedly affect the endothelial/fibroblast ratio (5.2 and 6.6)
though it progressively decreased the global activity when
compared to 2668/+38Luc. On the other hand, the further
deletion of 128 bp from the 59-end of region D (2124/+38Luc)
affected both the activity, which decreased by 41%, and the
endothelial/fibroblast ratio, which decreased from 7.0 to 3.7 when
compared to 2252/+38Luc.
Interestingly, removal of the conserved region D from the most
active 28409/+38 sequence resulted in an almost completely
silent 28409/+38mtDLuc reporter, with activity dropping 97% in
endothelial cells while the endothelial/fibroblast ratio fell from
20.3 to 4.4 when compared to 28409/+38Luc (Figure 4B),
confirming that region D plays a crucial role for expression of the
gene in endothelial cells.
Identification of the essential sequences within region D
In order to determine which parts of region D allowed high
expression levels in endothelial cells, a linker-scanning analysis of
its entire sequence was performed. This analysis corresponded to
the transfection of cells with a series of mutants of 2252/+38Luc
where a stretch of 20 bases was exchanged for a transcriptionnaly-
inactive sequence successively along the whole region [36].
Mutation of the sequences located between 2129 and 2109
(scanD-7) and between 2109 and 289 (scanD-8) induced a 99%
and a 70% drop in activity in endothelial cells when compared to
the scanD-6 levels, respectively (Figure 5A). Further, the
endothelial to fibroblast ratio was abolished with the scanD-8
mutant. This suggested that i) the scanD-7 and scanD-8 contain
essential sites for activation of the promoter in endothelial cells and
in fibroblasts, and ii) the scanD-8 region contains sites that are
specifically important for expression of the reporter in endothelial
cells.
Figure 3. 59-deletion study of the VE-statin/egfl7 promoter region. A. H5V endothelial (black bars) and L929 fibroblast (right, white bars) were
transfected with the pGL3basic luciferase reporter vector (Ctrl) or pGL3basic in which212969/+38 VE-statin/egfl7 promoter region or 59 deletions of it
were inserted. These reporters (80 fmoles) were transfected together with 54 fmoles pCH110 normalization vector. After 48h of culture, cells were
lyzed and the luciferase value of each sample was measured and normalized with its b-galactosidase value. Bars represent normalized activity as fold
over Ctrl mean value set to 1. Numbers associated with the black bars represent the calculated endothelial/fibroblast ratio of activity for the
corresponding construct. Left: scaled schematic representation of the constructs, names are given according to the cloned 59 and 39 end positions
relative to the exon-1b transcription start, Luc; luciferase. The experiment is representative of a set of at least three experiments performed in similar
conditions. Constructions were designed so that the luciferase gene was placed within exon-1b because initial experiments showed that placing it
where the coding sequence starts in exon-3 resulted in no detectable activity (not shown). ** p,0.01, * p,0.05. B. H5V endothelial cells (black bars)
or 3T3 fibroblasts (white bars) were transfected with 80 fmoles of pGL3promoter (Ctrl, Promega), 28409/27563SV40Luc, 27563/28409-SV40Luc, or
27770/27563-SV40Luc and with 54 fmoles of pCH110 normalization vector. After 48h of culture, cells were lyzed and the luciferase value of each
sample was measured and normalized with its b-galactosidase value. Bars represent normalized activity as fold over Ctrl mean value set to 1. Results
are displayed as in Figure 3A. The 28409/27563 fragment is active in endothelial cells regardless of orientation, the most active sequence in this
fragment corresponds to region A (27770/27563) which shows an endothelial/fibroblast ratio similar to the reporter containing the whole 28409/
27688 region.
doi:10.1371/journal.pone.0012156.g003
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Identification of individual functional sites within
region D
A computer analysis using the Genomatix suite performed on
the 2252/+38 sequence predicted the presence of one putative
CREB (2127), one MYB-binding site (2116), one GATA site
(2113) and an EBS head-to-head tandem (EBS6/EBS7, 2123/
2120) in the scanD-7 sequence, and one EBS (EBS5, 292) in
scanD-8 (Figure 5B). Among these, the CREB, MYB and EBS6/7
tandem sites are not conserved within mammals whereas the
GATA and EBS5 are perfectly conserved in all analyzed species,
including fishes (Figure S6). Among the sites that are not within
scanD-7 or scanD-8, EBS3 is perfectly conserved among species
whereas EBS4 is conserved with a functional substitution (GGAA
instead of GGAT) in chicken, stikleback, fugu, and medeka or a
one-base shift in marmoset (Figure S6). EBS3 and EBS4 are within
the scanD-9 sequence.
Experimental mutation of the GATA site induced a 64% and a
22% loss of activity of the initially most active 28409/+38Luc
reporter in endothelial and fibroblast cells, respectively
(Figure 6A). The most striking effects were obtained when
EBS5 was mutated in the originally most active 28409/+38Luc,
resulting in an almost inactive reporter, with a 97% and 89%
decrease of activity in endothelial cells and fibroblasts, respec-
tively (Figure 6B). This 2-bases mutation also abolished the
endothelial/fibroblast ratio. This mutation alone could thus
account for the effects observed with the scanD-8 mutant
(Figure 5A) or with the deletion of the entire region D in the
full length reporter (Figure 4B). Mutation of EBS3 markedly
affected activity, which dropped 87% and 75% in endothelial
cells and fibroblasts, respectively, thus decreasing the endothelial/
fibroblast ratio when compared to 28409/+38Luc. Mutation of
EBS4 reduced the activity of the reporter by 41% and 38% in
endothelial cells and fibroblasts, respectively. Mutation of EBS1
or of EBS2 did not significantly affect activity in endothelial cells,
although mutation of EBS1 doubled the endothelial/fibroblast
ratio when compared to 28409+/38Luc mainly because of a
drop of activity in fibroblasts. Mutation of EBS6 or of EBS7 did
not significantly affect activity in endothelial cells although
mutation of EBS6 doubled the endothelial/fibroblast ratio when
compared to 28409/+38Luc, as observed with the EBS1 mutant.
Erg, Fli-1 and GATA-2 are expressed at high levels in
endothelial cells
The previous results pinpointed the potential importance of
ETS and GATA transcription factors in the regulation of the VE-
statin/egfl7. In an attempt to identify the involved transcription
factors among these families, a comparison of the levels of
transcripts of all known ETS and GATA factors between MS1,
H5V, EOMA, and 1G11 endothelial cells and L929 (Figure S7)
and 3T3 fibroblasts (not shown) was performed. Among the six
GATA factors analyzed, GATA-2 was, by far, the most highly
expressed in endothelial cells when compared to L929, with
endothelial/fibroblast ratios ranging from 2268.5 (EOMA) to
57.462.0 (H5V). Regarding the ETS family, endothelial cells were
Figure 4. Region D is necessary for expression of the gene in endothelial cells. A. Right: H5V endothelial cells (black bars) and L929
fibroblasts (white bars) were transfected with the pGL3basic vector (Ctrl) or successive 59-deletion mutants of the 21768/+38Luc vector cloned into
pGL3basic (80 fmoles) and with 54 fmoles of pCH110 normalization vector. After 48h of culture, cells were lyzed and the luciferase value of each
sample was measured and normalized with its b-galactosidase value. Bars represent normalized activity as fold over Ctrl mean value set to 1. Results
are presented as in Figure 3A. The experiment is representative of a set of three performed in similar conditions. *** p,0.001, ns; not significant. The
most active sequence in the proximal promoter corresponds to the conserved region D within the 21768/+38 fragment. B. H5V endothelial cells
(black bars) and L929 fibroblasts (white bars) were transfected with 80 fmoles pGL3basic (Ctrl), 28409/+38Luc or the 28409/+38mtDLuc reporter
where region D had been removed and with 54 fmoles pCH110 normalization vector. After 48h of culture, cells were lyzed and the luciferase value of
each sample was measured and normalized with its b-galactosidase value. Bars represent normalized activity as fold over Ctrl mean value set to 1.
Results are represented as in Figure 3A. The experiment is representative of a set of three performed in similar conditions. *** p,0.001. While the
28409/+38 region provided high expression levels in endothelial cells when compared to fibroblasts, most of its activity was lost when region D was
removed from this construct.
doi:10.1371/journal.pone.0012156.g004
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mostly enriched in Erg and Fli-1 when compared to fibroblasts,
with endothelial/fibroblast ratios ranging from 692.260.0 to
909.060.0 for Erg and 26.960.0 to 102.260.6 for Fli-1, whereas
most other factors were expressed at levels close to those observed
in fibroblasts.
We then transfected L929 cells with the 2252/+38Luc reporter
or mutated versions of it together with expression vectors coding
for either GATA-2, GATA-4, Ets-1, Erg, or Fli-1 in order to assess
which of these transcription factors would transactivate this
promoter region. GATA-2 and GATA-4 transactivated the
2252/+38Luc construct (Figure 7A) while mutation of the GATA
site abolished the transactivation induced by both factors. In
similar assays, Erg, Fli-1, and Ets-1 transactivated the 2252/
+38Luc reporter (Figure 7B) and mutation of EBS5 abolished the
response to Fli-1 and to Ets-1 and decreased the response to Erg
by 86% when compared to Ctrl. Mutation of EBS4 did not
significantly affect the response of the promoter to Fli-1 or to Ets-1
and slightly decreased the response to Erg. Mutation of EBS3 had
no effects on the response to Fli-1 or to Ets-1 and increased the
response to Erg.
Thus, when over-expressed, Erg, Fli-1 and Ets-1 were able to
transactivate the proximal promoter region mainly through EBS5.
On the other hand, Erg, Fli-1 and Ets-1 cannot account for the
effects observed with the EBS3mt construct in Figure 6B,
suggesting that other ETS factors regulate the expression of the
gene through this site.
Figure 5. Identification of important sequences in region D. A. H5V endothelial cells (black bars) and L929 fibroblasts (white bars) were
transfected with 80 fmoles of either pGL3basic (Ctrl), the non-mutated 2252/+38Luc construct, or various mutated versions of it (scan D-2 to 14)
which corresponded to the successive exchange of 20bp of wild-type sequence for a 20bp transactivation-null cassette (black box), and with 54
fmoles of pCH110 normalization vector. After 48h of culture, cells were lyzed and the luciferase value of each sample was measured and normalized
with its b-galactosidase value. Bars represent normalized activity as fold over the Ctrl mean value set to 1. Results are displayed as in Figure 3A. The
experiment is representative of a set of three experiments performed in similar conditions. *** p,0.001. Mutation of the sequences corresponding to
scanD-7 and scanD-8 greatly affected the activity of the reporters, suggesting the presence of essential sites within these sequences. B. Sequence
and schematic representation of all the predicted transcription factor binding sites in the scanD-7 and scanD-8 sequence, and of the EBS in the2252/
+38 region of the gene. The 59 part of exon-1b is italicized. The sequences corresponding to the scanD-n mutants are underlined with double arrows.
The predicted binding sites which are conserved among species (Figure S6) are in bold.
doi:10.1371/journal.pone.0012156.g005
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Endogenous Erg and GATA-2 regulate the expression of
VE-statin/egfl7 in endothelial cells
In order to address the role of the endogenous transcription
factors on the regulation of the VE-statin/egfl7 gene in endothelial
cells, Erg, Fli-1, Ets-1, GATA-2 and GATA-4 were targeted using
RNA interference. siRNA-mediated down-regulation of the fli-1
transcripts (92%, Figure 8C) and that of erg (84%, Figure 8C)
induced a 53% and 65% drop of VE-statin/egfl7 levels in
endothelial cells, respectively (Figure 8A). On the other hand,
down-regulation of ets-1 (75%, Figure 8C) did not significantly
affect VE-statin/egfl7 expression. Down-regulation of GATA-2
(83%, Figure 8D) or of GATA-4 (90%, Figure 8D) induced a 63%
and 55% drop of VE-statin/egfl7 gene expression in endothelial
cells, respectively (Figure 8B).
These results were confirmed at the protein levels by Western-
blot analyses which showed that VE-statin/egfl7 accumulation was
impaired in cells treated with a siRNA targeting fli-1, erg, or, to a
slight extent, GATA-2, but not those targeting GATA-4 or Ets-1
(Figure 9). Interestingly, targeting fli-1 induced the repression of
GATA-2 (in addition to fli-1) and vice-versa, confirming previous
observations on this cross-regulation [37].
Finally, chromatin immunoprecipitation assays using endothe-
lial cell extracts showed that Erg and GATA-2 are present onto the
2252/+38 region of the VE-statin/egfl7 promoter in endothelial
cells (Figure 10) whereas Fli-1, Ets-1 and GATA-4 could not be
detected on this region, strongly suggesting that Erg and GATA-2
directly regulate the proximal region of the VE-statin/egfl7 gene
while Fli-1 would have an indirect regulatory role, possibly
through the regulation of GATA-2.
Discussion
The present work shows that the VE-statin/egfl7 gene is not
located in a large endothelial-specific cluster on chromosome 2.
Rather, its specific expression in endothelial cells depends on
epigenetic mechanisms and on the presence of an enhancer
located 8.4 kb ahead of the main transcription start site which
provides strong levels of expression in endothelial cells. The
proximal 2252/+38 promoter region also participates to the
Figure 6. Mutation analysis of GATA and ETS sites in the 2252/+38 region of the promoter. A. Right; H5V endothelial cells (black bars)
and L929 fibroblasts (white bars) were transfected with 80 fmoles of pGL3basic (Ctrl), 28409/+38Luc or a 28409/+38Luc mutant where the GATA
(GATAmt) site had been mutated, and with 54 fmoles pCH110 normalization vector. After 48h of culture, cells were lyzed and the luciferase value of
each sample was measured and normalized with its b-galactosidase value. Bars represent normalized activity as fold over Ctrl mean value set to 1.
Mutation of the GATA site (left, blackened circle) in the originally most active 28409/+38Luc vector resulted in a strong decrease of activity of the
reporter in endothelial cells and the endothelial/fibroblasts ratio was decreased by half when compared to 28409/+38Luc. The experiment is
representative of a set of three experiments performed in similar conditions. B. Right; H5V (black bars) and L929 (white bars) cells where transfected
with 80 fmoles of 28409/+38Luc or the indicated mutated versions in which the predicted EBS (left, numbered circles) were individually mutated by
site-directed mutagenesis (left, blackened numbered circles). After 48h of culture, cells were lyzed and the luciferase value of each sample was
measured and normalized with its b-galactosidase value. Bars represent normalized activity as fold over Ctrl mean value set to 1. Left; scaled
schematic representation of the28409/+38 wild-type region (top). The location of the GATA (circled G) and EBS (circled numbers) sites is represented
to scale along the zoomed region D of the mutants. Mutated sites are represented as blackened circles. Names of the constructs are given according
to the cloned 59 and 39 end positions relative to the exon-1b transcription start, Luc; luciferase. Results are presented according to Figure 3A. The
EBS6/EBS7 (2123/2120) tandem is located in scanD-7 of the linker scanning analysis, EBS5 (292) is located in scanD-8 and EBS4 (280), EBS3 (271),
EBS2 (249) and EBS1 (+28) are all located closer to the transcription start. The experiment is representative of a set of three performed in similar
conditions. *** p,0.001, ** p,0.01.
doi:10.1371/journal.pone.0012156.g006
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endothelial-specificity of expression of the gene, in particular
through essential ETS and GATA binding sites. This proximal
region is occupied by the Erg and GATA-2 transcription factors
which are both involved in the expression of the endogenous gene
in endothelial cells.
Region A, acting as an enhancer, was the most active region
identified by deletion analysis in vitro. However, despite a thorough
and frustrating analysis, we were not able to attribute a prominent
role to any discrete site or sub-region of this enhancer in the
regulation of expression of the gene, a situation similar to the
endothelial REn1 enhancer of the robo4 promoter [8]. Our data
altogether show that this region as a whole carries important
regulatory features. It may be involved in DNA-loop interactions
that would bring it in close proximity to the transcription start site
of the gene and favor transcription in endothelial cells, such as
reported for prolactin [38] or prostate specific antigen [39] but, so far,
we have no experimental data that could support this hypothesis.
Most of the information gathered here showed the importance
of the 2252/+38 region of the promoter. This region is necessary
for expression of the gene and is affected by epigenetic
modifications that increase the chromatin accessibility specifically
in endothelial cells. Among the conserved putative binding sites
that are present in this region, two EBS and one GATA are
essential for activity. Mutation of the GATA site in region D
resulted in the loss of half of the activity in endothelial cells,
underlining the important role of this site. GATA factors have
been frequently associated with endothelial gene expression;
important GATA sites are present in the promoters or enhancers
of genes like flk-1 [2], VE-cadherin [5], endothelin-1 [40], eNOS [41],
icam-2 [42], or vWF [43] and the presence of a GATA site has
been predicted in a putative endothelial and hematopoietic
promoter signature in a genome-wide analysis [44]. Our data
confirm that among the different GATA transcription factors, gata-
2 is markedly expressed in endothelial cells [45]. Interestingly, the
active GATA site in the VE-statin/egfl7 promoter matches the
canonical WGATAR sequence that allows high expression of gata-
2 itself in endothelial cells [46], suggesting that a similar regulation
could control VE-statin/egfl7 expression in these cells.
The involvement of EBS in the regulation of genes in
endothelial cells is also well documented. Such sites play essential
roles in the regulation of expression of flk-1, tie-1, tie-2, robo-4 or
VE-cadherin in endothelial cells [14,47]. Among the EBS analyzed,
the individual mutation of EBS3 or of EBS5 markedly affected the
activity of the reporter in endothelial and in fibroblast cells, but
Figure 7. Region D is transactivated by ETS and GATA factors. A. Right; L929 cells were transfected with 70 fmoles of pcDNA3 expression
vector (Ctrl, white bars) or with pcDNA3 constructs expressing the mouse GATA-2 (black bars) or GATA-4 (grey bars) and with the indicated Luc
reporter vectors (80 fmoles), together with 54 fmoles of pCH110 normalization vector. After 48h of culture, cells were lyzed and the luciferase value of
each sample was measured and normalized with its b-galactosidase value. Bars represent normalized activity as fold over the Ctrl mean value of
either Luc reporter set to 1. Left; scaled schematic representation of region D. The location of the GATA (circled G) and EBS (circled numbers) sites is
represented to scale along the schematized region D. Mutated sites are represented as blackened circles. Names of the constructs are given
according to the cloned 59 and 39 end positions relative to the exon-1b transcription start, LUC; luciferase. GATA-2 and GATA-4 transactivated the
wild-type 2252/+38 promoter region while mutation of the GATA site abolished the response of the promoter to these GATA factors. B. Right; L929
cells were transfected with 70 fmoles of pcDNA3 expression vector (Ctrl, white bars) or with pcDNA3 constructs expressing the mouse Ets-1 (black
bars), Erg (grey bars) or Fli-1 (dashed bars) and with 80 fmoles of the indicated Luc reporter vectors together with 54 fmoles of pCH110 normalization
vector. After 48h of culture, cells were lyzed and the luciferase value of each sample was measured and normalized with its b-galactosidase value.
Bars represent normalized activity as fold over the Ctrl mean value of either Luc reporter set to 1. Left; scaled schematic representation of region D.
The location of the GATA (circled G) and EBS (circled numbers) sites is represented to scale along the schematized region D. Mutated sites are
represented as blackened circles. Names of the constructs are given according to the cloned 59 and 39 end positions relative to the exon-1b
transcription start, Luc; luciferase. The 2252/+38 promoter region responds to Ets-1, Erg and Fli-1 and mutation of EBS5 abolished the response to
the ETS factors. Mutation of either EBS3 or of EBS4 had no effect on the response to Ets-1 or to Fli-1, however, mutation of EBS3 increased the
response to Erg, that of EBS4 decreased it, *** p,0.001, ** p,0.01, * p,0.05.
doi:10.1371/journal.pone.0012156.g007
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with a greater effect with EBS5. This suggests that these two sites
are necessary both for basal expression (in any cell type) and for
specific expression in endothelial cells. It was particularly striking
to see that the mutation of two bases of the EBS5 was sufficient to
abolish the activity of the long and most active 28409/+38Luc
reporter. Such dramatic effect pinpoints the crucial importance of
this site for expression of the gene.
Regarding the other EBS, mutation of EBS6 and that of EBS1
induced an interesting doubling of the endothelial/fibroblast ratio
when compared to 28409/+38Luc, mostly due to a decrease of
expression in fibroblasts. This probably explains the fact that the
scanD-7 mutant presented both a large drop in activity, which is
correlated to the loss of the GATA site, and a raise of the
endothelial/fibroblast ratio due to the mutation of EBS6.
Mutation of EBS2 lowered the endothelial/fibroblast ratio
probably because of a raise of activity in fibroblasts, suggesting
that an ETS repressor acts on this site in non-endothelial cells in
order to refrain expression. The ETS family contains transcrip-
tional repressors, such as Tel, Net and Erf among which Tel is
widely expressed in endothelial cells and participates to the
maintenance of the developing vascular network [48]. Interest-
ingly, Tel expression levels were 2.9 to 6.4-times higher in L929
fibroblasts than in endothelial cells, suggesting that this factor
could act as a repressor of VE-statin/egfl7 expression in non-
endothelial cells. However, we have yet no evidence that Tel
would affect VE-statin/egfl7 expression.
The levels of ETS factors in endothelial cells observed here are
in accordance with those measured earlier in several cell lines and
tissues in an expression profile analysis [49]. In this study, Erg was,
by far, the most highly expressed ETS factor in human endothelial
cells, followed by a group that included Fli-1, Sap1, Net, GAPBa
and Ets-2. Among the ETS factors that may regulate the EBS of
the VE-statin/egfl7 promoter, Erg and Fli-1 thus logically emerged
as potential candidates in regard to their very high expression in
endothelial cells versus fibroblasts (Figure S7B and [49]). In
addition, Erg and Fli-1 are co-expressed in the endothelium during
development [50,51] and act together and additively in order to
regulate angiogenesis in zebrafish, possibly through a co-regulation
Figure 8. Down-regulation of endogenous ETS and GATA factors in endothelial cells. A. H5V endothelial cells were transfected with siRNA
targeting fli-1, erg, or ets-1 (A), gata-2, or gata-4 (B) and cultured 48h before total RNA extraction and qPCR analysis of endogenous VE-statin/egfl7
expression. ** p,0.01, ns; not significant. Quantities are relative to mean value of the Ctrl siRNA set to 1. Down-regulation of Erg, Fli-1, gata-2 and
gata-4 resulted in a significant decrease in VE-statin/egfl7 expression levels. Specificity of the siRNA: qPCR analysis of expression levels of the erg, fli-1
and ets-1 (C) and of gata-2 and gata-4 (D) genes in response to either siRNA. Levels were normalized to the mean value obtained in response to
transfection to the Ctrl siRNA set to 1. All siRNA show a good specificity of inhibition toward their target and no significant side effects on the other
studied genes of the same family. Of note, the siRNA targeting Ets-1 down-regulates Fli-1 as well, as expected since Ets-1 controls the fli-1 gene in
endothelial cells [66].
doi:10.1371/journal.pone.0012156.g008
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of VE-cadherin [52]. The Erg transcription factor regulates the VE-
cadherin [53], and the endoglin promoters and enhancer together
with Fli-1 and Elf-1 [54]. It should be however noted that Erg loss-
of-function does not induce an overt vascular phenotype in
homozygous mutant mice, as blood vessels seem normal, even
though the primitive vascular network shows dilated vessels [55].
On the other hand, it was quite surprising to see that Ets-1 was not
more highly expressed in endothelial cells than in fibroblasts. Ets-1
Figure 9. Targeting of Fli-1, Erg and GATA-2 affects VE-statin/egfl7 protein accumulation in endothelial cells. H5V endothelial cells
were transfected with a control siRNA (siCtrl) of with siRNA targeting ets-1, fli-1, erg, gata-2, or gata-4, cultured for 48hr and analysed for protein
expression by SDS-PAGE and Western-blotting. VE-statin/egfl7 accumulation (boxed) is impaired when cells were treated with siRNA targeting fli-1,
erg and, and, to a slight extent, GATA-2, or when treated with a siRNA targeting VE-statin/egfl7 itself, used as positive control. Of note, there is a
cross-regulation between gata-2 and fli-1, as already reported in hematopoietic stem cells [37]. Specific bands are indicated by arrowheads. The Ets-1
band is distinguishable from a large non-specific band located immediately below [67].
doi:10.1371/journal.pone.0012156.g009
Figure 10. Endogenous Erg and GATA-2 are bound to the 2252/+38 region of the VE-statin/egfl7 promoter. H5V cell cultures were
treated with 1% formaldehyde, sonicated in order to produce 1000 bp average size DNA fragments and immunoprecipitation of the DNA-protein
complexes was performed using antibodies against HA.11 (irrelevant Ab, MMS-101R, Convance), Erg (sc-354x, Santa-Cruz), Fli-1 (sc-356x, Santa-Cruz),
Ets-1 (sc-111x, Santa Cruz), GATA-2 (sc-9008x, Santa-Cruz), or GATA-4 (sc-1237x, Santa-Cruz) antibody. DNA was then purified and analyzed by semi-
quantitative PCR on the 2252/+38 promoter region of the endogenous VE-statin/egfl7 gene. INPUT; 3.5% of total DNA, No Ab; no antibody added,
Irrel Ab; irrelevant IgG added. Levels were measured by semi-quantitative PCR using oligonucleotides that span the 2252/+38 region of the gene.
Data are expressed as 22DCt where DCt = Ct of sample – Ct of INPUT. The experiment is representative of a set of three performed in similar
conditions. *** p,0.001, * p,0.05.
doi:10.1371/journal.pone.0012156.g010
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is expressed in endothelial cells during development [56] and has
repeatedly been associated with endothelial gene expression when
used in over-expression approaches, including that of flk-1, tie and
VE-cadherin [57]. However, the various ets-1 gene inactivation
approaches that were reported did not relate any vascular defects
that would give Ets-1 a major role in the endothelial fate
[58,59,60]. On the other hand, a gene co-inactivation approach
recently showed that Ets-1 and Ets-2 are together involved in
vessel branching and endothelial survival [61]. This illustrates the
importance of redundancy of action between ETS factors for
specific gene expression, including that of Ets-1 in endothelial cells.
Mutation of EBS3 induced a marked decrease in promoter
activity while this mutant still responded to Erg, Fli-1 and Ets-1 in
transactivation assays, suggesting that other ETS factors are
involved in the regulation of the proximal VE-statin/egfl7 promoter
in endothelial cells. Few other ETS factors have a documented
role in vasculogenesis or angiogenesis; the etv2/EtsRP71 gene
inactivation prevents the emergence of the endothelial lineage and
the angiopoietin receptor tie-2 is a direct target gene of this
transcription factor [62]. Similarly, elk-3/net/sap-2 inactivation
induces dilated lymphatics [63] and etv-6/tel inactivation induces a
lack of vitelline vessels [48]. The fact that neither Etv2/EstRP71,
Elk-3/Net/Sap-2 nor Etv-6/Tel were up-regulated here in
endothelial cells does not exclude the possibility that these ETS
factors regulate VE-statin/egfl7 expression in endothelial cells
without being prominently expressed.
Interestingly, a RYMAAYA consensus sequence is present in
region D of the mouse VE-statin/egfl7 at 2207/2212, in tandem
with a putative EBS. This sequence corresponds to the proposed
Forkhead sequence that, when combined with an EBS, is
suggested to be important for the regulation of genes in endothelial
cells [13,14]. However, this sequence is present at this location
only in the mouse VE-statin/egfl7 sequence, it is not conserved
among species, including rat and human (Figure S6). Second, it is
located in the sequences corresponding to scanD-2 and scanD-3
sequences which global activity and endothelial/fibroblast ratio
were not affected by mutation (Figure 5A). It is therefore unlikely
that this putative Forkhead/EBS in region D plays an important
role in the regulation of the VE-statin/egfl7 gene in endothelial cells.
This raises the importance of experimentally validating such site
prediction.
It was recently observed that the microRNA miR-126 located in
the seventh intron of the VE-statin/egfl7 gene is specifically
expressed in endothelial cells [64]. Although it is not yet
demonstrated, it is probable that this microRNA arises from the
VE-statin/egfl7 pre-mRNA and depends on the same regulation
mechanisms. A briefly described analysis showed that miR-126
expression is dependent on the presence of two regions containing
ETS binding sites, one of which responds to the over-expression of
Ets-1 [64]. Interestingly, a sequence located in the present region
D and which contains EBS5 and EBS4 provided an endothelial-
specific pattern of expression [64]. This observation correlates well
with our results here showing the importance of this region for
expression of the gene in endothelial cells. However, since tissue-
specific co-regulation of a microRNA and of its host gene are not
strictly linked [65], whether the expression of VE-statin/egfl7 and
that of miR-126 are regulated by similar mechanisms in
endothelial cells remains to be investigated.
Supporting Information
Figure S1 Histone modifications along the 59 region of the VE-
statin/egfl7 gene A. Levels of acetylated histone H4 along the 59
region of the VE-statin/egfl7 gene. H5V endothelial cells (N, black
bars) and L929 (%, white bars) fibroblast cells were processed for
chromatin immunoprecipitation as described in Figure 2 using an
anti-acetyl-histone H4 antibody (06-866, Millipore). Inset: Acet-
ylated Histone H4 levels of the negative control b-globin and the
positive control VE-cadherin gene promoters taken as non- and
highly-expressed genes in endothelial cells, respectively. Semi-
quantitative PCR were performed in order to amplify various
locations along the promoter represented as the x-axis. Quantities
are relative to the diluted INPUT mean value set to 1.
Found at: doi:10.1371/journal.pone.0012156.s001 (0.15 MB TIF)
Figure S2 Na butyrate releases expression of VE-statin/egfl7 in
non-endothelial cells HeLa cells (white bars) and H5V (black bars)
were treated with 2 mM Na butyrate for 72 hr, lysed, total RNA
isolated and VE-statin/egfl7 mRNA levels quantified by qPCR
(see Material and Methods). Values are normalized to GAPDH
levels of the corresponding samples, levels of untreated cells are set
to 1.
Found at: doi:10.1371/journal.pone.0012156.s002 (0.04 MB TIF)
Figure S3 Identification of conserved regions between the
mouse and human VE-statin/egfl7 promoters. 20kb of mouse and
human VE-statin/egfl7 gene promoter sequences located upstream
of exon-3 were aligned using BLASTN v2.2.6 (www.ncbi.nlm.nih.
gov/blast/). Sequences with more than 80% identity located in
corresponding positions and in the same strand direction were
used to define the conserved A to E regions. The identified
conserved regions are represented to scale on the promoter region
as lettered gray boxes, the exons as numbered black boxes, the two
transcription starts are represented as arrows.
Found at: doi:10.1371/journal.pone.0012156.s003 (0.42 MB TIF)
Figure S4 The mouse promoter is functional in human primary
endothelial cells. Right: Human primary endothelial HUVEC cells
(black bars) were transfected with pGL3basic (Ctrl) or pGL3basic
in which the 212969/+38 VE-statin/egfl7 promoter region or 59
deletions of it were inserted. These reporters (80 fmoles) were
transfected together with 54 fmoles pCMV-bGal normalization
vector. After 48h of culture, cells were lyzed and the luciferase
value of each sample was measured and normalized with its b-
galactosidase value. Bars represent normalized activity as fold over
Ctrl mean value set to 1. Left: scaled schematic representation of
the constructs, names are given according to the cloned 59 and 39
end positions relative to the exon-1b transcription start, Luc;
luciferase. The experiment is representative of a set of two
experiments performed in similar conditions, ** p,0.01.
Found at: doi:10.1371/journal.pone.0012156.s004 (0.06 MB TIF)
Figure S5 Linker-scanning analysis of the 28409/27530
region. H5V endothelial cells (black bars) and L929 fibroblasts
(white bars) were transfected with 80 fmoles of pGL3basic (Ctrl),
28409/+38Luc or mutated versions of this vector (scan A-1 to -6)
corresponding to the successive exchange of 20bp of wild-type for
a 20bp transactivation-null cassette in the 27770/27570 region
and with 54 fmoles of pCH110 normalization vector. After 48h of
culture, cells were lyzed and the luciferase value of each sample
was measured and normalized with its b-galactosidase value. Bars
represent normalized activity as fold over Ctrl mean value set to 1.
Results are displayed as in Figure 3A. The experiment is
representative of sets of three experiments performed in similar
conditions. No sub-region was reliably found to be important for
activity of this sequence.
Found at: doi:10.1371/journal.pone.0012156.s005 (0.07 MB TIF)
Figure S6 Conservation analysis of the VE-statin/egfl7 region D
in vertebrates. Pairwise alignments of vertebrate genomic
sequences were realized using the comparative genomics tool
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(30-Way Multiz Alignment & Conservation) of the UCSC/Penn
State genome browser utilities (http://genome.ucsc.edu) with the
mouse VE-statin/egfl7 gene as template. Conserved putative
binding sites are boxed, bases matching the expected consensus
are bolded.
Found at: doi:10.1371/journal.pone.0012156.s006 (0.77 MB TIF)
Figure S7 A. Expression levels of GATA transcription factors
were measured by RT-qPCR using total RNA isolated from L929
fibroblasts and from 1G11, H5V, EOMA, and MS1 endothelial
cells. Levels are normalized to GAPDH quantities and are
represented as folds over the levels measured in L929 cells, using
the DDCt method. Y-axis scales are Log10 representations. The
oligonucleotide pairs used for each transcript and the qPCR
conditions are described in Table S3 and in the Material and
Methods sections, respectively. B. Expression levels of ETS
transcription factors were measured using qPCR in cDNA isolated
from L929 fibroblasts and from 1G11, H5V, EOMA, and MS1
endothelial cells. Levels are normalized to GAPDH quantities and
are represented as folds over the levels measured in L929 cells,
using the DDCt method. Y-axis scales are Log10 representations.
The oligonucleotide pairs used for each transcript and the qPCR
conditions are described in Table S3 and in the Materials and
Methods sections, respectively.
Found at: doi:10.1371/journal.pone.0012156.s007 (0.28 MB TIF)
Table S1 Primers used for site-directed mutagenesis and linker
scanning analysis. Primers are listed in the 59R39 orientation.
Found at: doi:10.1371/journal.pone.0012156.s008 (0.07 MB
DOC)
Table S2 Primers and conditions used in qPCR analysis
following ChIP. Primers are listed in the 59R39 orientation.
Found at: doi:10.1371/journal.pone.0012156.s009 (0.03 MB
DOC)
Table S3 Primers used in qPCR. Primers are listed in the 59R39
orientation.
Found at: doi:10.1371/journal.pone.0012156.s010 (0.05 MB
DOC)
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